VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VRDNViridian Therapeutics, Inc.
$30.12$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksVRDNCash Flow

Viridian Therapeutics, Inc. (VRDN) Cash Flow Statement

14Y historyFree accessUpdated daily

Operating cash flow tracked net losses closely with OCF/NI ratios between 0.71 and 2.45, and with no dividends, buybacks, or acquisitions across the period, capital was fully directed toward clinical activity, leaving free cash flow at -$93.1M in 2026Q3 and -$226.3M in 2026Q2.

Income StatementBalance SheetCash FlowRatios

VRDN Cash Flow Statement

Annual statement

VRDN Cash Flow Statement

Viridian Therapeutics, Inc. (VRDN) cash flow statement — 14-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash from Operations-341.5M-276.39M-232.32M-184.17M-93.84M-54.58M-29.78M-36.06M-26.84M-28.17M-7.23M-6.9M-2.21M-1.17M-6.22M
Operating CF Margin %--390.11%-76926.82%-58652.87%-5295.6%-1842.09%-2836.1%-808.25%-320.1%-703.65%-216.69%-271.79%-51.23%-27.05%-141.28%
Operating CF Growth %-10.92%-18.97%-26.14%-96.26%-71.92%-83.29%17.41%-34.32%4.7%-289.53%-4.83%-211.7%-89.5%81.24%-
Net Income-453.58M-342.6M-269.95M-237.73M-129.87M-79.41M-110.72M-41.87M-32.7M-26.51M-12.67M-11.33M-7.89M-2.16M-5.62M
Depreciation & Amortization701K460K540K522K255K120K239K288K281K308K341K184K144K148.31K144.29K
Stock-Based Compensation59.59M44.3M42.15M67.17M19.77M14.46M3.65M3.97M3.68M2.41M2.11M3.02M4.3M07.96K
Deferred Taxes00000056K-432K-416K0868K0177K0-1.64M
Other Non-Cash Items2.22M-1.58M-14.66M-4.71M54K8.52M72.57M340K376K94K-59K132K953K1.49M2.49M
Working Capital Changes49.56M23.03M9.6M-9.43M15.96M1.72M4.43M1.65M1.94M-4.47M2.18M1.1M105K-649.45K-1.61M
Change in Receivables-29.78M0102K0349K-451K99K-84K1.43M-1.44M-130K694K-271K201.59K-369.58K
Change in Inventory-85K0000000-57.8M-50.9M123K-8K178K-187.1K166.39K
Change in Payables-766K6.56M-73K-12.04M11.52M1.66M-426K525K-335K-101K2.03M633K383K-279.73K-1.29M
Cash from Investing-468.98M-37.56M-228.65M-94.25M-115.13M-74.29M-50.48M28.23M-29.91M1.03M-3K-95K-274K5.68K-119.43K
Capital Expenditures-1.94M-495K-511K-898K-797K-338K-42K-84K-445K-246K-3K-123K-266K-4.77K-106.91K
CapEx % of Revenue7.37%0.7%169.21%285.99%44.98%11.41%4%1.88%5.31%6.15%0.09%4.85%6.16%0.11%2.43%
Acquisitions00000029.37M-28.31M01.28M00000
Investments---------------
Other Investing-10M000079K-3K28.31M-29.46M1.28M028K-8K10.45K-12.52K
Cash from Financing815M426.74M457.74M225.67M322.24M125.28M101.31M70K41.92M52.47M-257K12.71M7.4M1.26M5.81M
Debt Issued (Net)224.18M28.88M015M5M0-8.57M-2.33M05.33M-333K-76K753K2.04M6.58M
Equity Issued (Net)483.07M348.33M478.66M201.26M335.87M131.2M116.1M2.4M44.53M48.56M012.73M6.64M-500K0
Dividends Paid0000000000000-285K-720K
Share Repurchases0000000000-173K-363K0-500K0
Other Financing107.75M49.54M-20.92M9.41M-18.63M-5.93M-6.22M0-2.61M-1.43M76K50K0-78-50K
Net Change in Cash4.51M112.79M-3.23M-52.75M113.28M-3.6M21.05M-7.76M-14.84M25.34M-7.49M5.71M4.91M96.81K-538.66K
Free Cash Flow-343.44M-276.89M-232.83M-185.07M-94.64M-54.92M-29.82M-36.14M-27.29M-28.41M-7.23M-7.02M-2.48M-1.17M-6.33M
FCF Margin %-1305.42%-390.81%-77096.03%-58938.85%-5340.58%-1853.49%-2840.1%-810.13%-325.41%-709.79%-216.78%-276.64%-57.38%-27.16%-143.71%
FCF Growth %-5.24%-18.92%-25.81%-95.56%-72.32%-84.16%17.48%-32.43%3.96%-292.77%-3.03%-183.22%-111.42%81.48%-
FCF per Share-3.03-3.27-3.43-4.14-2.95-4.61-8.38-17.30-13.83-22.15-10.03-13.01-16.48-6.23-34.03
FCF Conversion (FCF/Net Income)0.76x0.81x0.86x0.77x0.72x0.69x0.27x0.86x0.82x1.06x0.57x0.61x0.28x0.54x0.86x
Interest Paid-1.12M01.82M0293K0000000000
Taxes Paid000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway versus Phase 3 funding

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Losses Driven by Cash Burn

According to reported quarterly figures, VRDN's operating cash flow tracked its net loss closely, with OCF/NI ratios ranging from 0.71 to 2.45 across the ten quarters, indicating that reported losses are predominantly cash-consumptive rather than accounting-driven.

Because operating cash outflows roughly match net losses, the earnings quality question is less about accruals and more about the absolute size of the burn. Stock-based compensation of $30.4M in 2026Q2 narrows the gap in some quarters but does not change the underlying picture of sustained cash consumption. Investors should monitor whether the ratio stabilizes as R&D spending plateaus, since erratic quarterly swings in conversion appear driven more by working capital timing than by any improvement in cash generation.

Free Cash Flow Deeply Negative Throughout

As reported in financial statements, VRDN's free cash flow margin reached -796.9% in 2026Q2 and -848.8% in 2026Q1, with only modest improvement to -3.6% in 2026Q3 driven largely by lumpy milestone revenue rather than cost discipline.

The margin trajectory is distorted by revenue timing, so the more informative signal is the absolute FCF outflow, which has ranged from roughly $24M to $226M per quarter. The 2026Q3 margin improvement reflects a revenue spike against a relatively stable cash burn, not a structural shift in operating economics. This suggests the company's funding need remains largely independent of milestone receipts, warranting close attention to runway.

Asset-Light Model With Minimal Reinvestment

Based on EDBL's reported figures, VRDN's capital expenditures remained immaterial at under $1.3M in every reported quarter, with CapEx/Revenue ratios swinging widely only because the revenue denominator is erratic.

Negligible capital spending is consistent with a clinical-stage company outsourcing trial execution and manufacturing rather than owning infrastructure. The spikes in CapEx/Revenue, such as 181.8% in 2025Q4, reflect milestone revenue volatility rather than any rise in investment intensity. Because capital needs are minimal, the funding burden sits almost entirely in operating outflows tied to clinical programs.

No Shareholder Returns, All Cash to Trials

As reported in financial statements, VRDN paid no dividends and executed no buybacks or acquisitions across the ten reported quarters, directing all available capital toward operating and clinical activity.

The absence of shareholder distributions is expected for a pre-commercial biotech, and it means every dollar of cash is allocated to funding the THRIVE and THRIVE-2 programs. The company's low leverage, with debt-to-equity of roughly 0.07%, preserves flexibility, but the cash position against quarterly burn of $90M to $225M implies that future equity issuance may be necessary. Investors should weigh the potential for dilution as the primary capital allocation outcome.

Burn Rate Threatens Trial Funding Path

Based on reported figures, VRDN's recent quarterly operating outflows of roughly $90M to $225M, set against a stated cash position near $212M, suggest limited headroom for completing Phase 3 programs without additional capital.

The cash position appears to cover only a small number of quarters at recent burn levels, which may indicate that a financing event is needed before late-stage readouts. Management commentary on Lumvoa's early launch could improve the revenue outlook, but commercial revenue does not yet appear to offset clinical spending. This analysis is an inference from reported figures and warrants further investigation into the company's disclosed runway guidance.

VRDN — Frequently Asked Questions

Quick answers to the most common questions about buying VRDN stock.

How much cash does Viridian Therapeutics, Inc. (VRDN) generate from operations?

Viridian Therapeutics, Inc. (VRDN) generated $-276.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Viridian Therapeutics, Inc.'s free cash flow?

Viridian Therapeutics, Inc. (VRDN) reported negative free cash flow of $276.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Viridian Therapeutics, Inc.'s capital expenditure (CapEx)?

Viridian Therapeutics, Inc. (VRDN) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.